@FierceBiotech: Roche picks Sanford-Burnham chief to revive lagging research group. Story | Follow @FierceBiotech
@JohnCFierce: Looks like Mene Pangalos, champion of virtual development, eliminating fixed costs, comes out on top of AZ R&D. Release | Follow @JohnCFierce
@RyanMFierce: Pharma's got blockbuster hopefuls on the move in 2013, but a special lack of Alzheimer's meds in the mix. More | Follow @RyanMFierce
> Belgium's Galapagos NV is adding to its discovery engine with the acquisition of U.K.-based Cangenix, which does structure-based discovery work. Release
> Quoting insiders, Bloomberg reports that Pfizer ($PFE) is among the suitors considering a possible offer for Strides Arcolabs' injectable medicines unit. Story
> Denver-based InDevR has spun off ViroCyt, securing funding from a group of investors led by High Country Venture. Release
Pharma News
@FiercePharma: Here's a novel job-preserving approach: U.K. politician urges NHS to use more of AstraZeneca's Brilinta to stave off job cuts. More | Follow @FiercePharma
@AlisonBFierce:Who gave you the flu? A new Facebook app helps you place the blame. Article | Follow @AlisonBFierce
> Tired of empty shelves, CVS stops stocking Tylenol in some stores. Story
> Forest's Lexapro plague lingers with 41% hit to Q3 sales. News
> New AZ chief sends top execs packing in management shuffle. Report
@FierceMedDev: ArthroCAD draws Series A for surgical device development. Story | Follow @FierceMedDev
@MarkHFierce: Given Imaging ended exploration of a possible sale or merger--for now, the PillCam maker will go it alone. More | Follow @MarkHFierce
@DamianFierce: Covidien wants to see if its Hawk devices can work in combo PAD treatment, a potentially lucrative market. Report | Follow @DamianFierce
> Saliva gland could be secret to a Parkinson's disease Dx. Story
> St. Jude hit with FDA warning letter over Durata manufacturing. News
Biotech Research News
> Stem cells cut heart damage in muscular dystrophy mice. News
> Targeting VEGF could do more harm than good in the eye. More
> Stem cells show early promise in ALS. Item
Pharma Manufacturing News
> Private equity firm lays out $212 million for API maker. News
> Spain's Idifarma sweats the small stuff. Story
> New manufacturing issues lead AbbVie to 2nd Synthroid recall. Article
> Stem cells show early promise in ALS. More
And Finally… A Massachusetts General Hospital study concludes that generic drugs are cheaper but less effective than their newer rivals. And simpler dosing schedules make compliance more likely, investigators add. Story